主要组织相容性复合体I类分子Mamu - A*01的表达与猿猴免疫缺陷病毒SIVmac239复制的控制相关。
Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication.
作者信息
Mothé Bianca R, Weinfurter Jason, Wang Chenxi, Rehrauer William, Wilson Nancy, Allen Todd M, Allison David B, Watkins David I
机构信息
Wisconsin Regional Primate Research Center, University of Wisconsin, 1220 Capitol Court, Madison, WI 53715-1299, USA.
出版信息
J Virol. 2003 Feb;77(4):2736-40. doi: 10.1128/jvi.77.4.2736-2740.2003.
Abstract
Several HLA alleles are associated with attenuated human immunodeficiency virus disease progression. We explored the relationship between the expression of particular major histocompatibility complex (MHC) class I alleles and viremia in simian immunodeficiency virus SIV(mac)239-infected macaques. Of the common MHC class I alleles, animals that expressed Mamu-A*01 exhibited the best control of viral replication.
摘要
几种人类白细胞抗原（HLA）等位基因与人类免疫缺陷病毒疾病进展减缓相关。我们探讨了特定主要组织相容性复合体（MHC）I类等位基因的表达与感染猿猴免疫缺陷病毒SIV（mac）239的猕猴病毒血症之间的关系。在常见的MHC I类等位基因中，表达Mamu - A*01的动物对病毒复制的控制最佳。
相似文献
1
Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication.主要组织相容性复合体I类分子Mamu - A*01的表达与猿猴免疫缺陷病毒SIVmac239复制的控制相关。
J Virol. 2003 Feb;77(4):2736-40. doi: 10.1128/jvi.77.4.2736-2740.2003.
2
Rhesus Macaques Vaccinated with , , and Manifest Early Control of SIVmac239 Replication.恒河猴接种 、 、 和 后，早期控制 SIVmac239 复制。
J Virol. 2018 Jul 31;92(16). doi: 10.1128/JVI.00690-18. Print 2018 Aug 15.
3
Mamu-B*08-positive macaques control simian immunodeficiency virus replication.Mamu - B*08阳性猕猴可控制猿猴免疫缺陷病毒复制。
J Virol. 2007 Aug;81(16):8827-32. doi: 10.1128/JVI.00895-07. Epub 2007 May 30.
4
The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication.高频主要组织相容性复合体I类等位基因Mamu - B*17与猿猴免疫缺陷病毒SIVmac239复制的控制相关。
J Virol. 2006 May;80(10):5074-7. doi: 10.1128/JVI.80.10.5074-5077.2006.
5
Infection with "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques.感染“逃逸”病毒变体损害了Mamu - B*08阳性猕猴对猿猴免疫缺陷病毒SIVmac239复制的控制。
J Virol. 2009 Nov;83(22):11514-27. doi: 10.1128/JVI.01298-09. Epub 2009 Sep 2.
6
Patterns of CD8+ immunodominance may influence the ability of Mamu-B*08-positive macaques to naturally control simian immunodeficiency virus SIVmac239 replication.CD8 +免疫显性模式可能会影响Mamu - B*08阳性猕猴自然控制猿猴免疫缺陷病毒SIVmac239复制的能力。
J Virol. 2008 Feb;82(4):1723-38. doi: 10.1128/JVI.02084-07. Epub 2007 Dec 5.
7
Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes.含有Mamu - B*17单倍型的遗传并不能预测对猿猴免疫缺陷病毒SIVmac239的控制。
J Virol. 2007 Jan;81(1):406-10. doi: 10.1128/JVI.01636-06. Epub 2006 Nov 1.
8
Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive simian immunodeficiency virus-infected rhesus macaques.全面的免疫学评估显示，在精英控制者和疾病进展者中，感染猴免疫缺陷病毒且Mamu - B*17呈阳性的恒河猴之间的差异出奇地少。
J Virol. 2008 Jun;82(11):5245-54. doi: 10.1128/JVI.00292-08. Epub 2008 Apr 2.
9
MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys.MHC I类等位基因影响感染猿猴免疫缺陷病毒的恒河猴的病毒载量设定点和存活时间。
J Immunol. 2002 Sep 15;169(6):3438-46. doi: 10.4049/jimmunol.169.6.3438.
10
The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers.主要组织相容性复合体II类等位基因Mamu-DRB1*1003和-DRB1*0306在一群感染猿猴免疫缺陷病毒的恒河猴精英控制者中富集。
J Virol. 2008 Jan;82(2):859-70. doi: 10.1128/JVI.01816-07. Epub 2007 Nov 7.
引用本文的文献
1
Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques.感染SIV的中国恒河猴的免疫改变与病毒储存库图谱
Infect Dis Rep. 2025 Feb 6;17(1):12. doi: 10.3390/idr17010012.
2
Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques.恒河猴感染猴免疫缺陷病毒（SHIV）后诱导产生的针对 HIV-1 的中和抗体与新生儿免疫相关。
Nat Commun. 2024 Nov 27;15(1):10302. doi: 10.1038/s41467-024-54753-6.
3
4
Immunotoxin-mediated depletion of Gag-specific CD8+ T cells undermines natural control of SIV.免疫毒素介导的 Gag 特异性 CD8+ T 细胞耗竭削弱了 SIV 的自然控制。
JCI Insight. 2024 Jun 17;9(14):e174168. doi: 10.1172/jci.insight.174168.
5
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.双重免疫疗法诱导 SHIV 感染的 ART 抑制恒河猴持久缓解。
Science. 2024 Mar 8;383(6687):1104-1111. doi: 10.1126/science.adf7966. Epub 2024 Feb 29.
6
The Impact and Effects of Host Immunogenetics on Infectious Disease Studies Using Non-Human Primates in Biomedical Research.宿主免疫遗传学对生物医学研究中使用非人灵长类动物进行传染病研究的影响
Microorganisms. 2024 Jan 12;12(1):155. doi: 10.3390/microorganisms12010155.
7
Host immunity associated with spontaneous suppression of viremia in therapy-naïve young rhesus macaques following neonatal SHIV infection.宿主免疫与新生恒河猴感染 SHIV 后未经治疗的年轻恒河猴体内病毒血症的自发抑制有关。
J Virol. 2023 Nov 30;97(11):e0109423. doi: 10.1128/jvi.01094-23. Epub 2023 Oct 24.
8
Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.恒河猴新生儿感染 SHIV 可引发针对 HIV-1 的中和抗体。
Cell Rep. 2023 Mar 28;42(3):112255. doi: 10.1016/j.celrep.2023.112255. Epub 2023 Mar 14.
9
Long-read assembly of major histocompatibility complex and killer cell immunoglobulin-like receptor genome regions in cynomolgus macaque.食蟹猴主要组织相容性复合体和杀伤细胞免疫球蛋白样受体基因组区域的长读长组装。
Biol Direct. 2022 Nov 29;17(1):36. doi: 10.1186/s13062-022-00350-w.
10
V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques.V2 热点优化的 MVA 疫苗表达稳定的 HIV-1 型 C 群包膜 Gp140，可延迟 Mamu-A*01 阴性恒河猴对异源 C 群 2 级挑战的获得。
Front Immunol. 2022 Jul 22;13:914969. doi: 10.3389/fimmu.2022.914969. eCollection 2022.
本文引用的文献
1
Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection.急性期细胞毒性T淋巴细胞逃逸是猿猴免疫缺陷病毒感染的一个标志。
Nat Med. 2002 May;8(5):493-9. doi: 10.1038/nm0502-493.
2
Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection.病毒感染急性期，针对由单个主要组织相容性复合体I类分子所结合表位的CD8应答占主导。
J Virol. 2002 Jan;76(2):875-84. doi: 10.1128/jvi.76.2.875-884.2002.
3
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.基于金丝雀痘病毒载体-猴免疫缺陷病毒gag-pol-env的疫苗接种以及猕猴主要组织相容性复合体I类（A*01）延缓猴免疫缺陷病毒SIVmac诱导的免疫缺陷。
J Virol. 2002 Jan;76(1):292-302. doi: 10.1128/jvi.76.1.292-302.2002.
4
Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.急性和慢性HIV感染中HIV特异性细胞毒性T细胞特异性的显著差异。
J Exp Med. 2001 Jan 15;193(2):181-94. doi: 10.1084/jem.193.2.181.
5
CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.来自感染猿猴免疫缺陷病毒的恒河猴的CD8(+)淋巴细胞识别由主要组织相容性复合体I类分子Mamu-A*01结合的14种不同表位：对疫苗设计和测试的意义。
J Virol. 2001 Jan;75(2):738-49. doi: 10.1128/JVI.75.2.738-749.2001.
6
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.在原发性病毒血症消退期间，针对Tat的细胞毒性T淋巴细胞会选择SIV逃逸变体。
Nature. 2000 Sep 21;407(6802):386-90. doi: 10.1038/35030124.
7
Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape.细胞毒性T淋巴细胞对人类免疫缺陷病毒的反应：控制与逃逸
Stem Cells. 2000;18(4):230-44. doi: 10.1634/stemcells.18-4-230.
8
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.HLA B*5701与HIV感染的长期非进展者亚组中病毒复制的受限高度相关。
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14. doi: 10.1073/pnas.050567397.
9
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.病毒特异性细胞毒性T淋巴细胞反应选择猿猴免疫缺陷病毒Env和Nef中的氨基酸变异。
Nat Med. 1999 Nov;5(11):1270-6. doi: 10.1038/15224.
10
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.人类白细胞抗原与人类免疫缺陷病毒1型：杂合子优势及B*35-Cw*04劣势
Science. 1999 Mar 12;283(5408):1748-52. doi: 10.1126/science.283.5408.1748.
Zotero 插件